SETD6 and prostate carcinoma: To test this hypothesis, we used DU145 prostate cancer cell lines stably expressing Flag-E2F1 WT or Flag-E2F1 K117R mutant in SETD6 WT and SETD6 KO context that have been described in our previous study [25] and were characterized with respect to the expression of SETD6 and the different forms of E2F1 (Supplementary Fig. S1).